EVITA TEST COMPLETE and EVITA TEST GENDER are developed by the Danish biotech company ARCEDI Biotech in close collaboration with Aarhus University Hospital. A dedicated research team Since 2007, ARCEDI's employees, together with Aarhus University Hospital and some other hospitals in Denmarks, have worked to develop cell-based

A dedicated research team
Since 2007, ARCEDI, together with Aarhus University Hospital and some other hospitals in Denmark, have worked to develop cell-based Noninvasive Prenatal Test (cbNIPT) by isolating rare fetal cells from the blood samples from pregnant women. This pioneering work has lead to the development of technology behind EVITA TEST COMPLETE.

In has been known for many decades that during pregnancy fetal cells do end up into maternal blood circulation. If isolated and analyzed they can be an excellent source to perform high resolution NIPT. However, rarity of these cells in pregnant woman’s blood has hindered the development of a reliable technology for performing cell-based NIPT.

However, the perseverance of ARCEDI’s scientists lead to the development of patented and robust technology of isolating and analyzing these fetal cells.

A unique product
EVITA TEST COMPLETE is a revolution for pregnant couples who want to know about their unborn child’s chromosomes. The test is based on blood sample – and is thus completely without the risk to the baby and with minimal discomfort to the pregnant woman. EVITA TEST COMPLETE differs from other non-invasive prenatal tests (NIPT) as it gives a result for all fetal chromosomes. We are proud of our product, which can do more than the conventional NIPT and unlike the CVS, is completely risk-free for the fetus. 

An ambition to open new doors
ARCEDI´s patented technology has the potential to make a noticeable difference and analyze fetuses for many other serious diseases. It is in our DNA to continue our research, and and achieve new goals to provide security and certainty in pregnancy to as many people as possible. 

If you want to know more about ARCEDI, you can see more on ARCEDI’s website.

ARCEDI's Mission

Our mission is to provide pregnant women a safe, simple and accurate cell-based non-invasive prenatal diagnosis (cbNIPD) by isolating and extracting fetal calls from maternal blood for genomic analysis of the fetus.

ARCEDI's Vision

Our vision is to fundamentally transform prenatal diagnostics by making cell-free non-invasive prenatal testing (cfNIPT), chorionic villus sampling (CVS) and amniocentesis (Amnio) obsolete.

If you want to know more about ARCEDI, please visit our website.


ARCEDI has two offices in Denmark:

Tabletvej 1
DK-7100 Vejle

INCUBA, Palle Juul-Jensens Boulevard 82 DK-8200 Aarhus N

For additional information:

Lotte Hatt, Chief Scientific Officer 
Mail: loha@arcedi.com 
Phone: +45 61 71 25 57